nextMONARCH 1: Phase 2 study of abemaciclib plus tamoxifen or abemaciclib alone in HR+, HER2-advanced breast cancer

dc.contributor.authorHamiton, E.
dc.contributor.authorCortes, J.
dc.contributor.authorDieras, V.
dc.contributor.authorOzyilkan, O.
dc.contributor.authorChen, S-C.
dc.contributor.authorPetrakova, K.
dc.contributor.authorManikhas, A.
dc.contributor.authorJerusalem, G.
dc.contributor.authorHegg, R.
dc.contributor.authorLu, Y.
dc.contributor.authorBear, M.M.
dc.contributor.authorJohnston, E.L.
dc.contributor.authorMartin, M.
dc.date.accessioned2020-12-24T07:55:14Z
dc.date.available2020-12-24T07:55:14Z
dc.date.issued2019
dc.identifier.issn0008-5472en_US
dc.identifier.issue4en_US
dc.identifier.urihttp://hdl.handle.net/11727/5135
dc.identifier.volume79en_US
dc.identifier.wos000478677002388en_US
dc.language.isoengen_US
dc.relation.isversionof10.1158/1538-7445.SABCS18-PD1-11en_US
dc.relation.journalCANCER RESEARCHen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titlenextMONARCH 1: Phase 2 study of abemaciclib plus tamoxifen or abemaciclib alone in HR+, HER2-advanced breast canceren_US
dc.typeconferenceObjecten_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: